Articles From: Data from Ongoing Phase 2 Studies of Rucaparib in Ovarian Cancer Demonstrate Safety and Clinical Activity, Validate Differentiated Strategy to Dataram Regains Compliance for Continued Listing on NASDAQ


Clovis Oncology (NASDAQ:CLVS) today announced preliminary Phase 2 results from the ARIEL2 ( A ssessment of R ucaparib I n Ovarian Canc e r Tria l ) study and updated results from the ongoing Phase 1/2 monotherapy study of rucaparib.
Sign-up for Data from Ongoing Phase 2 Studies of Rucaparib in Ovarian Cancer Demonstrate Safety and Clinical Activity, Validate Differentiated Strategy investment picks
95% (19/20) Overall Response Rate (ORR) in Patients with High-Risk CLL, the patient population to be studied in recently announced Phase 3 Clinical Trial being conducted under Special Protocol Assessment (SPA) 87% (34/39) ORR per iwCLL criteria in all evaluable CLL patients plus an additional 10% of patients with a nodal PR or nodal reductions ranging from 20%-45% without disease progression 88% (7/8) ORR in all evaluable Mantle Cell Lymphoma (MCL) patients with a 38% (3/8) Complete Response rate Combination of TG-1101 + Ibrutinib well tolerated with limited Grade 3/4 events reported to date SAN FRANCISCO, Dec.
Sign-up for Data From Phase 2 Clinical Trial of TG-1101 (Ublituximab) and Ibrutinib Shows Compelling Clinical Activity in Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia (CLL) investment picks
DANVERS, Mass., Sept.
Sign-up for Data From RECOVER RIGHT Impella RP Trial to be Announced at TCT 2014 investment picks
Data Group Ltd.
Sign-up for Data Group Ltd. announces third quarter results for 2014 investment picks
http://media.marketwire.com/attachments/201004/586398_dataiologo.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1152104&ProfileId=051205&sourceType=1 REDMOND, WA --
Sign-up for Data I/O Corporation to Announce Third Quarter 2014 Financial Results on October 30, 2014 investment picks
http://media.marketwire.com/attachments/201004/586398_dataiologo.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1162170&ProfileId=051205&sourceType=1 REDMOND, WA --
Sign-up for Data I/O Engages SM Berger & Company as Investor Relations Firm investment picks
http://media.marketwire.com/attachments/201004/586398_dataiologo.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1155302&ProfileId=051205&sourceType=1 REDMOND, WA --
Sign-up for Data I/O Reports Third Quarter 2014 Results investment picks
http://media.marketwire.com/attachments/201004/586398_dataiologo.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1160100&ProfileId=051205&sourceType=1 REDMOND, WA --
Sign-up for Data I/O to Present at LD Micro Conference on December 3rd investment picks
http://media.marketwire.com/attachments/201004/586398_dataiologo.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1148682&ProfileId=051205&sourceType=1 REDMOND, WA --
Sign-up for Data I/O's New PSV3000 Wins Global Technology's Award for Programming investment picks
Front-runner in Managed and Cloud Services for Oracle Technologies and Applications Marks Five-Year Anniversary of Specialized Application Engineering Team and Completes Major Upgrade for Haemonetics Corporation BEDFORD, Mass.
Sign-up for Data Intensity Fortifies Track Record of Success in Oracle EBS R12 Implementations and Upgrades investment picks
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today early study findings demonstrating an overall response rate of 18.5 percent with KEYTRUDA, the company’s anti-PD-1 therapy, as assessed by RECIST v1.1, central review (n=5/27), in PD-L1 positive, advanced triple-negative breast cancer – one of the most aggressive forms of breast cancer.
Sign-up for Data Investigating KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Advanced Triple-Negative Breast Cancer Presented at 2014 San Antonio Breast Cancer Symposium investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today early study findings demonstrating that KEYTRUDA ® (pembrolizumab), the company’s anti-PD-1 therapy, achieved an overall response rate of 66 percent, as assessed by International Harmonization Project response criteria (n=19/29: 95% CI, 46-82), in transplant-ineligible and failure patients with relapsed/refractory classical Hodgkin Lymphoma (cHL) whose disease progressed on or after treatment with brentuximab vedotin.
Sign-up for Data Investigating KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Classical Hodgkin Lymphoma Presented at ASH Annual Meeting investment picks
Survey of CIOs and IT Decision Makers Highlights Storage and Data Management as a Critical Factor to Operational Success; Points to Software and Active Archive as Growth Opportunities SAN JOSE, Calif.
Sign-up for Data Is Currency Of New Economy, But Most Fail To Unlock Its Full Value; HGST Survey Finds 86% Of Data Center Decision-Makers Surveyed Believe That All Data Has Value investment picks
-- First-Line Use of Brincidofovir for CMV May Preserve Subsequent Therapeutic Options --
Sign-up for Data on Chimerix's Brincidofovir Suggests Favorable Resistance Profile in Adenovirus and Cytomegalovirus (CMV) investment picks
http://media.marketwire.com/attachments/201207/48976_Astellas_logo.jpg http://media.marketwire.com/attachments/201203/41309_medivation_logo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1164742&ProfileId=051205&sourceType=1 SAN FRANCISCO, CA and TOKYO, JAPAN --
Sign-up for Data Presented From Phase 2 Study of Enzalutamide in Advanced Androgen-Receptor Positive, Triple-Negative Breast Cancer investment picks
http://media.marketwire.com/attachments/201406/75933_logo1.jpg http://media.marketwire.com/attachments/201310/67907_gsk_logo.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1152248&ProfileId=051205&sourceType=1 LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA --
Sign-up for Data Published on Anoro(R) Ellipta(R) Demonstrate Improved Lung Function Compared to Tiotropium investment picks
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced a retrospective data analysis from the CHAMPION clinical trial showing significant a reduction in 30-day hospital readmission rates for patients age 65 and older.
Sign-up for Data Shows the CardioMEMS HF System Significantly Reduced 30-Day Hospital Readmission Rates investment picks
http://media.marketwire.com/attachments/201404/243780_Peregrine_logo_CMYK_sanspharm.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1164678&ProfileId=051205&sourceType=1 TUSTIN, CA --
Sign-up for Data to Be Presented at 2014 San Antonio Breast Cancer Symposium Demonstrate Immune-Stimulatory Properties of Peregrine Pharmaceuticals' Bavituximab in Models of Breast Cancer investment picks
2014/10/9
API Integration to Benefit DataCandy Partners MONTREAL , Oct.
Sign-up for DataCandy Partners With Blackhawk Network (Canada) To Power Digital Gift Cards investment picks
Datalink (Nasdaq: DTLK), a leading provider of data center infrastructure and services, announced today that it will issue a news release on Tuesday October 21, 2014, at approximately 3:00 p.m. Central Time to announce third quarter operating results for 2014.
Sign-up for Datalink 2014 Third Quarter Operating Results Conference Call investment picks
Datalink (Nasdaq:DTLK), a leading provider of data center infrastructure and services, today announced an agreement to acquire privately held Bear Data Solutions, Inc. (Bear). The acquisition of San Francisco-based Bear will quadruple Datalink’s West Coast revenue base to more than $200 million, expand its Cisco expertise into strategically important new areas, and add more than 1,000 new midmarket and enterprise customers to whom Datalink can market its comprehensive portfolio of data center offerings.
Sign-up for Datalink Acquires IT Solutions Provider Bear Data Solutions, Inc. investment picks
Datalink (Nasdaq: DTLK), a leading provider of data center infrastructure and services, today announced that Paul Lidsky, president and CEO, and Greg Barnum, chief financial officer, are scheduled to present at the following investor conferences: About Datalink A complete data center solutions and services provider for Fortune 500 and mid-tier enterprises, Datalink transforms data centers so they become more efficient, manageable and responsive to changing business needs.
Sign-up for Datalink Announces Upcoming Investor Conferences investment picks
Datalink (Nasdaq: DTLK), a leading provider of data center infrastructure and services, today reported results for its third quarter and nine months that ended September 30, 2014.
Sign-up for Datalink Reports 2014 Third Quarter and Nine Month Operating Results investment picks
2014/11/18
On November 17, 2014, Dataram Corporation (the “Company”; NASDAQ:DRAM) and certain institutional investors, including Isaac Capital Group, as lead investor, closed a securities purchase agreement (the “Purchase Agreement”), pursuant to which the Company agreed to sell up to an aggregate of 1,300,000 shares of its Series A Preferred Stock (the “Series A Stock”), together with warrants to purchase shares of common stock, to such investors at a price of $5.00 per share (the “Preferred Stock Transaction”). The sale of the Series A Stock will take place in multiple tranches.
Sign-up for Dataram Announces Sale of up to $6.5 Million of Series A Preferred Stock, Election of New Directors and Other Results of Shareholders’ Meeting investment picks
2014/10/21
On October 20, 2014, Dataram Corporation (the “Company”) and certain investors entered into a securities purchase agreement (the “Purchase Agreement”), pursuant to which the Company agreed to sell up to an aggregate of 1,300,000 shares of its Series A Preferred Stock (the “Series A Stock”) together with warrants to purchase shares of common stock, to such investors at a price of $5.00 per share (the “Preferred Stock Transaction”). The sale of the Series A Stock will take place in multiple tranches.
Sign-up for Dataram Announces Sale of up to $6.5 Million Series A Preferred Stock and Set New Shareholders Meeting Date investment picks
2014/12/3
On December 3, 2014, Dataram Corporation (the “Company”) announced that on December 2, 2014, the Company was notified by the NASDAQ Stock Market, LLC that, based upon the Company’s submission of the appropriate documentation, the Company has demonstrated compliance with the minimum $2,500,000 stockholders’ equity requirement for continued listing on The NASDAQ Capital Market.
Sign-up for Dataram Regains Compliance for Continued Listing on NASDAQ investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Data from Ongoing Phase 2 Studies of Rucaparib in Ovarian Cancer Demonstrate Safety and Clinical Activity, Validate Differentiated Strategy to Dataram Regains Compliance for Continued Listing on NASDAQ
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent